Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C20H14BrN5O and a molecular weight of approximately 420.26 g/mol. It belongs to the class of bromodiphenyl ethers and features a pyrazolo[3,4-c]pyridazine core structure. The compound is listed as experimental and has not been approved for any medical use or entered clinical trials as of now. There is no available information on its mechanism of action, biological targets, or therapeutic indications in public databases. Its primary relevance appears to be in chemical biology or medicinal chemistry research rather than as an established pharmaceutical agent.[1][2][3][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[2-bromo-4-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-methylbenzonitrile.